{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:25Z","timestamp":1791245185002,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jaccao.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:17:07Z","timestamp":1750169827000},"page":"430-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy"],"prefix":"10.1016","volume":"7","author":[{"given":"Anthony F.","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau T.","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaya S.","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akriti","family":"Mishra Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"DeFusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Oligino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Drullinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanu","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Oeffinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Steingart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jaccao.2025.05.006_bib1","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jaccao.2025.05.006_bib2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaccao.2025.05.006_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial","volume":"34","author":"Advani","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jaccao.2025.05.006_bib4","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.jaccao.2025.05.006_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.jaccao.2025.05.006_bib6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"10.1016\/j.jaccao.2025.05.006_bib8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.6004\/jnccn.2021.0023","article-title":"NCCN guidelines insights: breast cancer, version 4.2021","volume":"19","author":"Gradishar","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"16","key":"10.1016\/j.jaccao.2025.05.006_bib9","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaccao.2025.05.006_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jaccao.2025.05.006_bib11","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jaccao.2025.05.006_bib12","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaccao.2025.05.006_bib13","first-page":"13","article-title":"Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy","volume":"9","author":"Yu","year":"2023","journal-title":"Cardiooncology"},{"issue":"1","key":"10.1016\/j.jaccao.2025.05.006_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-017-4362-x","article-title":"Cardiac safety of nonanthracycline trastuzumab-based therapy for HER2-positive breast cancer","volume":"166","author":"Yu","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.jaccao.2025.05.006_bib15","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.jaccao.2025.05.006_bib16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaccao.2024.06.005","article-title":"Cardiovascular Considerations during cancer therapy: gaps in evidence and JACC: CardioOncology expert panel recommendations","volume":"6","author":"Leong","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.jaccao.2025.05.006_bib17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jaccao.2024.07.017","article-title":"Cardiovascular considerations before cancer therapy: gaps in evidence and JACC: CardioOncology expert panel recommendations","volume":"6","author":"Raisi-Estabragh","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"3","key":"10.1016\/j.jaccao.2025.05.006_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jaccao.2025.05.006_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2015.3709","article-title":"Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer","volume":"2","author":"Dang","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jaccao.2025.05.006_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jaccao.2025.05.006_bib21","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jaccao.2025.05.006_bib22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S1470-2045(13)70384-X","article-title":"Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study","volume":"14","author":"Jones","year":"2013","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.jaccao.2025.05.006_bib23","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jaccao.2025.05.006_bib24","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","article-title":"Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial","volume":"28","author":"Procter","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jaccao.2025.05.006_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEART study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jaccao.2025.05.006_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity, a phase I trial","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.jaccao.2025.05.006_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2021.01.011","article-title":"BSE and BCOS guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and\/or trastuzumab","volume":"3","author":"Dobson","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"30","key":"10.1016\/j.jaccao.2025.05.006_bib28","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2018.77.9736","article-title":"Risk-imaging mismatch in cardiac imaging practices for women receiving systemic therapy for early-stage breast cancer: a population-based cohort study","volume":"36","author":"Thavendiranathan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaccao.2025.05.006_bib29","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.3390\/curroncol28060427","article-title":"A randomized trial comparing 3- versus 4-monthly cardiac monitoring in patients receiving trastuzumab-based chemotherapy for early breast cancer","volume":"28","author":"Dent","year":"2021","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.jaccao.2025.05.006_bib30","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","article-title":"Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients","volume":"11","author":"Henry","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.jaccao.2025.05.006_bib31","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2020.03.002","article-title":"Cardiotoxicity surveillance and risk of heart failure during HER2 targeted therapy","volume":"2","author":"Yu","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"12","key":"10.1016\/j.jaccao.2025.05.006_bib32","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1001\/jamaoncol.2020.4749","article-title":"Early trastuzumab interruption and recurrence-free survival in ERBB2-positive breast cancer","volume":"6","author":"Copeland-Halperin","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jaccao.2025.05.006_bib33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-014-3029-0","article-title":"Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival","volume":"146","author":"Wang","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.jaccao.2025.05.006_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-016-3823-y","article-title":"Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study","volume":"157","author":"Gong","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"10.1016\/j.jaccao.2025.05.006_bib35","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/jama.2019.13978","article-title":"Waste in the US health care system: estimated costs and potential for savings","volume":"322","author":"Shrank","year":"2019","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.jaccao.2025.05.006_bib36","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1001\/jama.2017.16193","article-title":"The high costs of unnecessary care","volume":"318","author":"Carroll","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jaccao.2025.05.006_bib37","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jacc.2018.10.038","volume":"73","author":"Doherty","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jaccao.2025.05.006_bib38","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaccao.2025.05.006_bib39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaccao.2025.05.006_bib40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaccao.2025.05.006_bib41","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087325001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T01:13:03Z","timestamp":1750295583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087325001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2666087325001577"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.05.006","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}